Literature DB >> 26922254

Decline in the Development of New Anesthetics.

Kamen V Vlassakov1, Igor Kissin2.   

Abstract

The number of new anesthetics approved by the USA FDA over the past 30 years (1985-2014) is much smaller than during the preceding 30 years (1955-1984): four versus ten. Investigational anesthetics clinically tested since 1990 have been almost exclusively intravenous anesthetics (nine compounds), with only one now approved by the FDA. All nine agents represent modifications of anesthetics introduced approximately 40-50 years ago; none demonstrates a truly novel mechanism of action. The apparent drought of novel anesthetics is difficult to explain. While there may be multiple reasons, we believe that one is especially noteworthy: the dramatic improvement in anesthesia safety owing to the context in which anesthetics are administered, effectively decreasing the pressure to develop new drugs with better safety margins.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Keywords:  anesthesia; anesthesia-related mortality; investigational drugs; pharmaceutical industry; therapeutic index

Mesh:

Substances:

Year:  2016        PMID: 26922254     DOI: 10.1016/j.tips.2016.01.009

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  2 in total

1.  Opioid prescriptions for pain and epidemic of overdose death: can the dramatic reduction in anesthesia mortality serve as an example?

Authors:  Igor Kissin
Journal:  J Pain Res       Date:  2016-06-28       Impact factor: 3.133

2.  Differential effects of the novel neurosteroid hypnotic (3β,5β,17β)-3-hydroxyandrostane-17-carbonitrile on electroencephalogram activity in male and female rats.

Authors:  Srdjan M Joksimovic; Dayalan Sampath; Kathiresan Krishnan; Douglas F Covey; Vesna Jevtovic-Todorovic; Yogendra H Raol; Slobodan M Todorovic
Journal:  Br J Anaesth       Date:  2021-05-08       Impact factor: 9.166

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.